HOME >> BIOLOGY >> NEWS
New Tests Demonstrate MuchLarger, More Specific Immune Responses To Viruses

"The beauty of the tetramer technology is that it can be applied to study T cell responses to any pathogen, from influenza to HIV to malaria. And tetramers give you both a more accurate and a much more rapid picture of the immune response," Dr. Altman explains. In his Science article, Dr. Doherty says that tetramer staining is "set to be the gold standard for quantifying virus-specific CD8+ T cells."

The Emory researchers also tested the CD8+ T cell response using sensitive assays that measure the production of interferon-gamma, a cytokine (a small protein secreted from a cell) produced by virus-specific T cells that is important in controlling the infection. The interferon-gamma assay also demonstrated a strong, virus-specific response by CD8+ T cells.

Studies using the LDA technique have underestimated the virus-specific T cell response, explains Dr. Ahmed, partly because it requires culturing the cells for one to two weeks, and only T cells that are capable of dividing and surviving for that long are counted. Since activated T cells are prone to die when restimulated with viral antigens, many of the antigen-specific T cells either die or do not divide enough to be counted.

After the initial CD8+ T cell viral response, about 95 percent of the T cells die and the remainder persist to become memory cells poised to respond to future invasions by the same virus. The assays used in the Emory study were also able to detect memory CD8+ T cells specific to the LCMV virus more than one year after infection.

"One of the hardest things to do is to identify T cells responding to a particular pathogen," explains Dr. Ahmed. "This work greatly revises our thinking on the dynamics of T cell activation and will lead us to re-examine our models of viral-induced T cell proliferation."

This research was supported by grants from the National Institutes of Health and the American Cancer Societ
'"/>

Contact: Holly Korschun
hkorsch@emory.edu
404/727-3990
Emory University Health Sciences Center
3-Jun-1998


Page: 1 2 3 4

Related biology news :

1. Tests show biotech corn rules need revision
2. Multicomponent Malaria Vaccine Shows Promise in Laboratory Tests
3. Urine Tests Will Do Better Than Pelvic Exams To Save Teens From Serious Effects Of Sexually Transmitted Diseases, UCSF Analysis Shows
4. In New Alzheimers Studies, Lab Tests Show Vitamin E And Other Antioxidants Preventing Brain Cell Death
5. Tracking Hepatitis C: Health Project Demos Worldwide Early-Warning System For Disease Outbreaks; Sandia Tests Disease-Tracking Approach
6. Early Tests Indicate Motor Skills Unharmed In Consumers Of Tainted Fish
7. Vion Demonstrates Readiness Of First Tumor-Targeting Salmonella For Human Testing Against Solid Tumors
8. Emory University Scientists Demonstrate New Pathway For Genetic Mutations In Everyday Cell Life
9. Vions TAPET Organisms Demonstrate Reduced Virulence, Increased Safety While Retaining Ability To Specifically Target Tumors
10. Wake Forest Physicians Demonstrate How Gene-Diet Interaction Affects Cholesterol Absorption
11. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus

Post Your Comments:
(Date:5/23/2013)... , the team reveal the interplay of brain chemicals ... the Wellcome Trust and BBSRC. , By changing ... our perceptual abilities. While these changes can affect the ... the fidelity of that response. , Lead ... you communicate with others, you can make yourself better ...
(Date:5/22/2013)... Forest Service scientists are part of "Landscapes of Resilience", ... Foundation, will examine how collaborative planning and stewardship of ... , The TKF Foundation announced today that Landscapes of ... funding. In addition to research on the role of ... the 3-year, $585,000 grant will contribute to the creation ...
(Date:5/22/2013)... working to improve durability in fuel cell powered ... have discovered links between electrode degradation processes and ... the effects of electrode degradation stressors in the ... lifetime. , The findings of the study, led ... latest in a long-term study at Burnaby-based Ballard ...
Breaking Biology News(10 mins):'Landscapes of Resilience' to study how people use nature as a source of recovery 2Tests lead to doubling of fuel cell life 2
(Date:5/23/2013)... May 23, 2013 PuraMed BioScience ® ... marketer of over-the-counter (OTC) medicinal and healthcare products, ... on the company based on low market capitalization ... Non-Prescription, All Natural Product to Treat Migraine Headaches ... #1 Prescription Competitor , Currently Available Nationwide ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 The ... encourage all types of inventions. They focus on learning ... noticing this community gravitate toward bringing their ideas to ... DIY Biology Movement, works on making projects using biology. ... DNA of plants to make them glow with bioluminescence ...
(Date:5/23/2013)... , May 23, 2013 VG ... strategic alliance with DAK Renewable Research to conduct ... oil yield. VG Energy is a majority owned ... VGLS). VG Energy,s exclusively licensed compound ... the oil yield in plants, possessing a wide ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. ... for pain has reached an important milestone, as Virobay ... VBY-036 - a selective cathepsin S inhibitor.   ... a double-blind, randomized, placebo-controlled study designed to evaluate the ... VBY-036 in healthy adults. "The initiation of ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
Cached News: